Fosun Pharma maintains high growth in its main business in the third quarter

It is understood that the significant growth of Fosun Pharma in the first three quarters was mainly attributable to the rapid growth of the company's drug R&D and manufacturing operations during the reporting period, the continued high-speed growth of the company's investment in the performance of Sinopharm Holdings, and certain assets. Sinopharm, China’s largest drug distribution company, continued to grow at a rapid rate. The net profit growth in the first three quarters exceeded 80%, and the market’s leading edge further expanded.

In drug R&D and manufacturing, sales of Fosun Pharma's core companies Shinseiyuan, Yakyu Pharmaceutical, and Wanbang Pharmaceutical all achieved breakthrough growth, and the leading products continued to maintain their leading position in their respective market segments.